Mohamed Sadek Abdel-Bakky

Prof. Mohamed Sadek Abdel-Bakky

Professaor
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2007 in Kidney International
Verified
Journal Article
Closed access
SKS. Keller
S. Keller
CRC. Rupp
C. Rupp
ASA. Stoeck
A. Stoeck
SRS. Runz
S. Runz
MFM. Fogel
M. Fogel
PAPeter Altevogt
Peter Altevogt

1 June 2009 in The American Journal of Pathology
Verified
Journal Article
Closed access
PGPaul Gutwein
Paul Gutwein
MAMohamed Sadek Abdel-Bakky
Mohamed Sadek Abdel-Bakky
ASAnja Schramme
Anja Schramme
KDKai Doberstein
Kai Doberstein
NKNicole Kämpfer-Kolb
Nicole Kämpfer-Kolb
JPJosef Pfeilschifter
Josef Pfeilschifter

1 February 2009 in European Journal of Cancer
Verified
Journal Article
Closed access
PGPaul Gutwein
Paul Gutwein
ASAnja Schramme
Anja Schramme
NSNina Sinke
Nina Sinke
MAMohamed Sadek Abdel-Bakky
Mohamed Sadek Abdel-Bakky
BVBeren Voss
Beren Voss
GKGlen Kristiansen
Glen Kristiansen

1 March 2010 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
PDF file
SLSophia B. Lee
Sophia B. Lee
ASAnja Schramme
Anja Schramme
KDKai Doberstein
Kai Doberstein
RDReinhard Dummer
Reinhard Dummer
MAMohamed Sadek Abdel-Bakky
Mohamed Sadek Abdel-Bakky
PGPaul Gutwein
Paul Gutwein

1 October 2018 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MEMohammed Elmowafy
Mohammed Elmowafy
KSKhaled Shalaby
Khaled Shalaby
MBMohamed M. Badran
Mohamed M. Badran
HAHazim M Ali
Hazim M Ali
MAMohamed Sadek Abdel-Bakky
Mohamed Sadek Abdel-Bakky
HIHussein M. Ibrahim
Hussein M. Ibrahim

1 September 2009 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
PGPaul Gutwein
Paul Gutwein
MAMohamed Sadek Abdel-Bakky
Mohamed Sadek Abdel-Bakky
KDKai Doberstein
Kai Doberstein
ASAnja Schramme
Anja Schramme
JBJanet Beckmann
Janet Beckmann
JPJosef Pfeilschifter
Josef Pfeilschifter
Diabetic nephropathy (DN) is a major cause of end-stage renal failure worldwide. Oxidative stress has been reported to be a major culprit of the disease and increased oxidized low density lipoprotein (oxLDL) immune complexes were found in patients with DN. In this study we present evidence, that CXCL16 is the main receptor in human podocytes mediating the uptake of oxLDL. In contrast, in primary tubular cells CD36 was mainly involved in the uptake of oxLDL. We further demonstrate that oxLDL down-regulated α3-integrin expression and increased the production of fibronectin in human podocytes. In addition, oxLDL uptake induced the production of reactive oxygen species (ROS) in human podocytes. Inhibition of oxLDL uptake by CXCL16 blocking antibodies abrogated the fibronectin and ROS production and restored α3 integrin expression in human podocytes. Furthermore we present evidence that hyperglycaemic conditions increased CXCL16 and reduced ADAM10 expression in podocytes. Importantly, in streptozotocin-induced diabetic mice an early induction of CXCL16 was accompanied by higher levels of oxLDL. Finally immunofluorescence analysis in biopsies of patients with DN revealed increased glomerular CXCL16 expression, which was paralleled by high levels of oxLDL. In summary, regulation of CXCL16, ADAM10 and oxLDL expression may be an early event in the onset of DN and therefore all three proteins may represent potential new targets for diagnosis and therapeutic intervention in DN.